A single-arm, phase II trial of neoadjuvant gemcitabine and S1 in patients with resectable and borderline resectable pancreatic adenocarcinoma: PREP-01 study
ConclusionsNAC-GS was feasible and actively prolonged survival following PDAC planned resection. Randomized control trials are needed to further clarify the survival benefit of NAC-GS in addition to surgery followed by adjuvant therapy.
Source: Journal of Gastroenterology - Category: Gastroenterology Source Type: research
More News: Adenocarcinoma | Borderline Tumor | Carbohydrates | Chemotherapy | Gastroenterology | Neoadjuvant Chemotherapy Therapy | Neoadjuvant Therapy | Pancreas | Pancreatic Cancer | Study